Abstract
The purpose of the study was to investigate clinical and pharmacokinetic parameters concerning perphenazine decanoate (PD) and haloperidol decanoate (HD) with an interval of 3 weeks during a study period of 51 weeks. This was done by using the available drug preparations in chronic schizophrenic patients in a randomised, double-blind, cross-over, multicentre study. In addition, an elimination phase of 6 weeks was added, when no IM injections of the depot drugs were given. Twenty-nine patients in a stable neuroleptic maintenance phase entered the study. The patients were rated during the trial according to the CPRS-SCHZ and CGI scales, the UKU side effect scale and serum concentrations of the drugs and prolactin were monitored. There was no significant difference between the drugs in antipsychotic efficacy or side effects. Thus, the doses were equipotent with regard to the CPRS-SCHZ scores. However, the patients' global improvement rating was higher for PD (52%) than for HD (39%) (P>0.05). The elimination of both drugs was very slow. No interaction effects between PD and HD were observed. The serum levels of HD were in most patients lower than those recommended for acute-subacute treatment. The mean doses were 117 mg (0.29 mmol), range 20–313 mg PD and 120 mg (0.32 mmol), range 20–350 mg HD. The serum concentrations in nmol/L of perphenazine and haloperidol (week 24) were 0.8–15.9 and 2.3–46.7, respectively.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altamura CA, Colarcurcio F, Mauri MC, Moro AR, De Novellis F (1990). Haloperidol Decanoat in Chronic Schizophrenia: A study of 12 months with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 14:25–35
Bech P, Malt U, Dencker SJ et al. (1993) Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatr Scand Suppl 372
Dahl SG (1986) Plasma level monitoring of antipsychotic drugs clinical utility. Clin Pharmacokinet 11:36–61
Dencker SJ, Lepp M, Malm U (1980) Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiatr Scand Suppl 279[61]:10–28
Eklund K, Forsman A (1991) Minimal effective dose and relapse — double-blind trial: haloperidol vs placebo. Clin Neuropharmacol Suppl 2[14]:7–15
Forsman A, Mårtensson E, Nyberg G, Öhman R (1974) A gas chromatographic method for determining haloperidol. A sensitive procedure for studying serum concentration and pharmacokinetics of haloperidol in patients. Naunyn Schmiedebergs Arch Pharmacol 286[2]:113–124
Green AI, Brown WA (1988) Prolactin and neuroleptic drugs. Endocrinol Metab Clin N Am 17:213–223
Kissling W (ed) (1991) Guidelines for neuroleptic relapse prevention in schizophrenia. Springer, Berlin Heidelberg
Kistrup K, Gerlach J, Aaes-Jörgensen T, Larsen N-E (1991) Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Psychopharmacology 105:42–48
Knudsen P, Hansen LB, Larsen N-E (1985a) Depot neuroleptic treatment: Clinical and pharmacokinetic studies of pephenazine decanoate. Acta Psychiatr Scand Suppl 322[72]:51–74
Knudsen P, Hansen LB, Höjholdt K, Larsen N-E (1985b) Long-term depot neuroleptic treatment with perphenazine decanoate I: efficacy and side effects in a 12 month study of 42 drug monitored psychiatric patients. Acta Psychiatr Scand Suppl 322[72]:29–40
Larsson M, Axelsson R, Forsman A (1984) On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoat. Curr Ther Res 36:1071–1088
Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand 334. 76.
Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J (1991) Plasma levels of fluphenazine in patients receiving fluphenazine decanoate relationship to clinical response. Br J Psychiatry 158:658–665
McKane JP, Robinson ADT, Wiles DH, McCreadie RG, Stirling GS (1987) Haloperidol decanoat v. Fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychatry 151:333–336
Muuze RG (1980) Determination of serum levels of psychotropic drugs by liquid-solid chromatography. Proceedings of the 4th International Symposium on phenothiazines and structurally related drugs, pp 125–172
Omérov M, Wistedt B, Hansen-Bolvig L, Larsen N-E (1988) The relationship between perphenazine plasma levels and clinical response in acute schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 13:159–166
Perris C (1974) A multicentre multidimensional study of some new longacting neuroleptic drugs. Acta Psychiatr Scand Suppl 249
Reyntjens AJM, Heykants JJP, Woestenborghs RJH, Gelders YG, Aers TJL (1982) Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. Int Pharmacopsychiatry 17:238–246
Skantze K, Malm U, Dencker SJ, May PRA, Corrigan P (1992) Comparison of quality of life to standard of living in schizophrenic outpatients. Br J Psychiatriatry 161:797–801
Thapa K, Rowland LA (1989) Quality of life perspective sin long-term care: staff and patient perceptions. Acta Psychiatr Scand 80:267–271
Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou C-YJ, Crowner M, Douyon R (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49:354–361
Wistedt B (1981) A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 64:65–84
Wistedt B, Jörgensen A, Wiles D (1982) A depot neuroleptic withdrawal study. Plasma concentrations of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 78:301–304
Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Mölbjerg C (1991) Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand 84[1]:14–22
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dencker, S.J., Giös, I., Mårtensson, E. et al. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology 114, 24–30 (1994). https://doi.org/10.1007/BF02245440
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245440